1-3 of 3
Hanne Helfrich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20 + Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial

Thorsten Zenz, MD, Markus Kreuz, Doris Winter, Hanne Helfrich, Maxi Fuge, Heike Horn, MD, Julia Richter, PhD, Reiner Siebert, Lorenz Truemper, MD, Norbert Schmitz, MD, Markus Loeffler, Wolfram Klapper, Andreas Rosenwald, MD, Hartmut Döhner, MD, Michael Pfreundschuh, MD, German Ott, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2012) 120 (21): 546.
https://doi.org/10.1182/blood.V120.21.546.546
Published: 2012
Journal Articles

DNA damage–induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing

Julia Mohr, Hanne Helfrich, Maxi Fuge, Eric Eldering, Andreas Bühler, Dirk Winkler, Matthias Volden, Arnon P. Kater, Daniel Mertens, Doreen Te Raa, Hartmut Döhner, Stephan Stilgenbauer, Thorsten Zenz
Journal: Blood
Blood (2011) 117 (5): 1622–1632.
https://doi.org/10.1182/blood-2010-08-300160
Published: 2011
Includes: Supplemental data
Journal Articles

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Thorsten Zenz, Patrick Hoth, Raymonde Busch, Hanne Helfrich, Dirk Winkler, Andreas Bühler, Nancy Patten, Sim Truong, Lin Wu, Günther Fingerle-Rowson, Kirsten Fischer, Anna-Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael K. Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood
Blood (2009) 114 (22): 1267.
https://doi.org/10.1182/blood.V114.22.1267.1267
Published: 2009